Monika Kandebo
Overview
Explore the profile of Monika Kandebo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
155
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smith S, Toolan D, Kandebo M, Vardigan J, Raheem I, Layton M, et al.
J Pharmacol Exp Ther
. 2025 Feb;
392(1):100047.
PMID: 39893013
MK-8189 is a novel phosphodiesterase 10A (PDE10A) inhibitor being evaluated in clinical studies for the treatment of schizophrenia. PDE10A is a cyclic nucleotide phosphodiesterase enzyme highly expressed in medium spiny...
2.
Roecker A, Schirripa K, Loughran H, Tong L, Liang T, Fillgrove K, et al.
ACS Med Chem Lett
. 2023 Feb;
14(2):146-155.
PMID: 36793422
Parkinson's disease is the second most prevalent progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. Loss-of-function mutations in GBA, the gene that encodes for...
3.
Mahoney-Crane C, Viswanathan M, Russell D, Curtiss R, Freire J, Bobba S, et al.
J Neurosci
. 2023 Jan;
43(3):501-521.
PMID: 36639889
The most common genetic risk factor for Parkinson's disease (PD) is heterozygous mutations , which encodes for the lysosomal enzyme, glucocerebrosidase. Reduced glucocerebrosidase activity associates with an accumulation of abnormal...
4.
Layton M, Kern J, Hartingh T, Shipe W, Raheem I, Kandebo M, et al.
J Med Chem
. 2023 Jan;
66(2):1157-1171.
PMID: 36624931
PDE10A is an important regulator of striatal signaling that, when inhibited, can normalize dysfunctional activity. Given the involvement of dysfunctional striatal activity with schizophrenia, PDE10A inhibition represents a potentially novel...
5.
Zhang N, Hatcher N, Ekroos K, Kedia K, Kandebo M, Marcus J, et al.
J Lipid Res
. 2022 Apr;
63(6):100218.
PMID: 35489416
A major challenge of lipidomics is to determine and quantify the precise content of complex lipidomes to the exact lipid molecular species. Often, multiple methods are needed to achieve sufficient...
6.
Cosden M, Jinn S, Yao L, Gretzula C, Kandebo M, Toolan D, et al.
Neurobiol Dis
. 2021 Sep;
159:105507.
PMID: 34509608
Mutations in the lysosomal enzyme glucocerebrosidase (GCase, GBA1 gene) are the most common genetic risk factor for developing Parkinson's disease (PD). GCase metabolizes the glycosphingolipids glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph)....
7.
Polinski N, Martinez T, Gorodinsky A, Gareus R, Sasner M, Herberth M, et al.
PLoS One
. 2021 Jun;
16(6):e0252325.
PMID: 34106956
Multiple mutations have been described in the human GBA1 gene, which encodes the lysosomal enzyme beta-glucocerebrosidase (GCase) that degrades glucosylceramide and is pivotal in glycosphingolipid substrate metabolism. Depletion of GCase,...
8.
Zhao Z, Harrison S, Schubert J, Sanders J, Polsky-Fisher S, Zhang N, et al.
Bioorg Med Chem Lett
. 2016 May;
26(12):2952-2956.
PMID: 27133481
A series of N-heterocyclic pyridinone catechol-O-methyltransferase (COMT) inhibitors were synthesized. Physicochemical properties, including ligand lipophilic efficiency (LLE) and clogP, were used to guide compound design and attempt to improve inhibitor...
9.
Raheem I, Schreier J, Fuerst J, Gantert L, Hostetler E, Huszar S, et al.
Bioorg Med Chem Lett
. 2015 Nov;
26(1):126-32.
PMID: 26602277
Herein, we present the identification of a novel class of pyrazolopyrimidine phosphodiesterase 10A (PDE10A) inhibitors. Beginning with a lead molecule (1) identified through a fragment-based drug discovery (FBDD) effort, lead...
10.
Gentzel R, Toolan D, Roberts R, Koser A, Kandebo M, Hershey J, et al.
Neuropharmacology
. 2015 Jun;
99:256-63.
PMID: 26044638
Phosphodiesterase 10A (PDE10A) has garnered attention as a potential therapeutic target for schizophrenia due to its prominent striatal expression and ability to modulate striatal signaling. The present study used the...